Michael A Dyer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9109338/publications.pdf

Version: 2024-02-01

135 papers	11,548 citations	31976 53 h-index	30087 103 g-index
147 all docs	147 docs citations	147 times ranked	15355 citing authors

#	Article	IF	Citations
1	Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature Reviews Cancer, 2013, 13, 397-411.	28.4	632
2	Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma. Cell Reports, 2014, 7, 104-112.	6.4	583
3	Inactivation of the p53 pathway in retinoblastoma. Nature, 2006, 444, 61-66.	27.8	550
4	A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature, 2012, 481, 329-334.	27.8	442
5	Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. Cancer Discovery, 2014, 4, 1342-1353.	9.4	418
6	Control of MÃ¼ller glial cell proliferation and activation following retinal injury. Nature Neuroscience, 2000, 3, 873-880.	14.8	400
7	A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nature Medicine, 2020, 26, 792-802.	30.7	381
8	Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma. JAMA - Journal of the American Medical Association, 2012, 307, 1062.	7.4	379
9	Prox1 function controls progenitor cell proliferation and horizontal cell genesis in the mammalian retina. Nature Genetics, 2003, 34, 53-58.	21.4	364
10	Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. Cancer Cell, 2013, 24, 710-724.	16.8	252
11	TNF Counterbalances the Emergence of M2 Tumor Macrophages. Cell Reports, 2015, 12, 1902-1914.	6.4	232
12	Orthotopic patient-derived xenografts of paediatric solid tumours. Nature, 2017, 549, 96-100.	27.8	223
13	The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming, and Tumorigenesis. Neuron, 2017, 94, 550-568.e10.	8.1	222
14	Regulating proliferation during retinal development. Nature Reviews Neuroscience, 2001, 2, 333-342.	10.2	220
15	MDMX: from bench to bedside. Journal of Cell Science, 2007, 120, 371-378.	2.0	218
16	Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6685-6690.	7.1	207
17	A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nature Genetics, 2015, 47, 615-624.	21.4	207
18	p27^{Kip1}and p57^{Kip2}Regulate Proliferation in Distinct Retinal Progenitor Cell Populations. Journal of Neuroscience, 2001, 21, 4259-4271.	3.6	206

#	Article	IF	Citations
19	The search for the retinoblastoma cell of origin. Nature Reviews Cancer, 2005, 5, 91-101.	28.4	201
20	Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nature Genetics, 2004, 36, 351-360.	21.4	191
21	Six3-mediated auto repression and eye development requires its interaction with members of the Groucho-related family of co-repressors. Development (Cambridge), 2002, 129, 2835-2849.	2.5	177
22	Differentiated Horizontal Interneurons Clonally Expand to Form Metastatic Retinoblastoma in Mice. Cell, 2007, 131, 378-390.	28.9	174
23	Genomic landscape of paediatric adrenocortical tumours. Nature Communications, 2015, 6, 6302.	12.8	166
24	ATRX and DAXX: Mechanisms and Mutations. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026567.	6.2	153
25	The Genomic Landscape of Childhood and Adolescent Melanoma. Journal of Investigative Dermatology, 2015, 135, 816-823.	0.7	148
26	Targeting the DNA Repair Pathway in Ewing Sarcoma. Cell Reports, 2014, 9, 829-840.	6.4	141
27	Coexpression of Normally Incompatible Developmental Pathways in Retinoblastoma Genesis. Cancer Cell, 2011, 20, 260-275.	16.8	123
28	Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma. Clinical Cancer Research, 2005, 11, 7569-7578.	7.0	117
29	Retinoblastoma: One World, One Vision. Pediatrics, 2008, 122, e763-e770.	2.1	115
30	The First Knockout Mouse Model of Retinoblastoma. Cell Cycle, 2004, 3, 950-957.	2.6	113
31	Genetics and Epigenetics of Human Retinoblastoma. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 547-562.	22.4	109
32	St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discovery, 2021, 11, 1082-1099.	9.4	109
33	Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell, 2018, 34, 411-426.e19.	16.8	106
34	RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget, 2014, 5, 438-450.	1.8	104
35	Compensation by tumor suppressor genes during retinal development in mice and humans. BMC Biology, 2006, 4, 14.	3.8	92
36	The first knockout mouse model of retinoblastoma. Cell Cycle, 2004, 3, 952-9.	2.6	90

#	Article	IF	Citations
37	Targeting the p53 Pathway in Retinoblastoma with Subconjunctival Nutlin-3a. Cancer Research, 2011, 71, 4205-4213.	0.9	89
38	Quantification of Retinogenesis in 3D Cultures Reveals Epigenetic Memory and Higher Efficiency in iPSCs Derived from Rod Photoreceptors. Cell Stem Cell, 2015, 17, 101-115.	11.1	88
39	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	12.8	87
40	Six3-mediated auto repression and eye development requires its interaction with members of the Groucho-related family of co-repressors. Development (Cambridge), 2002, 129, 2835-49.	2.5	87
41	Synthetic lethality between Rb, p53 and Dicer or miR-17â€“92 in retinal progenitors suppresses retinoblastoma formation. Nature Cell Biology, 2012, 14, 958-965.	10.3	79
42	The neoepitope landscape in pediatric cancers. Genome Medicine, 2017, 9, 78.	8.2	77
43	Preclinical Models for Neuroblastoma: Establishing a Baseline for Treatment. PLoS ONE, 2011, 6, e19133.	2.5	77
44	Developmental sources of conservation and variation in the evolution of the primate eye. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8963-8968.	7.1	72
45	Nucleome Dynamics during Retinal Development. Neuron, 2019, 104, 512-528.e11.	8.1	70
46	Regulation of proliferation during central nervous system development. Seminars in Cell and Developmental Biology, 2005, 16, 407-421.	5.0	68
47	CONSERTING: integrating copy-number analysis with structural-variation detection. Nature Methods, 2015, 12, 527-530.	19.0	68
48	Analysis of MDM2 and MDM4 Single Nucleotide Polymorphisms, mRNA Splicing and Protein Expression in Retinoblastoma. PLoS ONE, 2012, 7, e42739.	2.5	68
49	MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nature Communications, 2020, 11, 913.	12.8	66
50	The Homeodomain Proteins Prox1, Six3 and Chx10 Regulate Proliferation, Cell Fate Specification and Differentiation in the Developing Retina. Cell Cycle, 2003, 2, 347-354.	2.6	65
51	The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Developmental Biology, 2016, 411, 287-293.	2.0	63
52	Retinal Cell Type DNA Methylation and Histone Modifications Predict Reprogramming Efficiency and Retinogenesis in 3D Organoid Cultures. Cell Reports, 2018, 22, 2601-2614.	6.4	63
53	ATRX binds to atypical chromatin domains at the 3â€² exons of zinc finger genes to preserve H3K9me3 enrichment. Epigenetics, 2016, 11, 398-414.	2.7	59
54	Preparation and square wave electroporation of retinal explant cultures. Nature Protocols, 2006, 1, 2710-2718.	12.0	58

#	Article	IF	Citations
55	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clinical Cancer Research, 2015, 21, 3216-3229.	7.0	58
56	The inherited blindness associated protein AIPL1 interacts with the cell cycle regulator protein NUB1. Human Molecular Genetics, 2002, 11, 2723-2733.	2.9	53
57	Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration. Drug Metabolism and Disposition, 2011, 39, 15-21.	3.3	53
58	Use of Preclinical Models to Improve Treatment of Retinoblastoma. PLoS Medicine, 2005, 2, e332.	8.4	52
59	Retinoblastoma: From the Two-Hit Hypothesis to Targeted Chemotherapy. Cancer Research, 2007, 67, 7547-7550.	0.9	48
60	Retinoblastoma from human stem cell-derived retinal organoids. Nature Communications, 2021, 12, 4535.	12.8	48
61	Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer, 2011, 117, 421-434.	4.1	46
62	Retinal degeneration in Aipl1-deficient mice: a new genetic model of Leber congenital amaurosis. Molecular Brain Research, 2004, 132, 208-220.	2.3	45
63	N-myc coordinates retinal growth with eye size during mouse development. Genes and Development, 2008, 22, 179-193.	5.9	45
64	The p57Kip2 cyclin kinase inhibitor is expressed by a restricted set of amacrine cells in the rodent retina. Journal of Comparative Neurology, 2001, 429, 601-614.	1.6	44
65	ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. Cancer Cell, 2019, 36, 512-527.e9.	16.8	44
66	Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma. Mini-Reviews in Medicinal Chemistry, 2016, 16, 430-454.	2.4	42
67	Regulation of proliferation, cell fate specification and differentiation by the homeodomain proteins Prox1, Six3, and Chx10 in the developing retina. Cell Cycle, 2003, 2, 350-7.	2.6	41
68	Targeting MDM2 and MDMX in Retinoblastoma. Current Cancer Drug Targets, 2007, 7, 689-695.	1.6	40
69	The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. Molecular Cancer Research, 2019, 17, 895-906.	3.4	40
70	Neuronal Differentiation and Synaptogenesis in Retinoblastoma. Cancer Research, 2007, 67, 2701-2711.	0.9	38
71	Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget, 2013, 4, 844-859.	1.8	37
72	Genetic and Epigenetic Discoveries in Human Retinoblastoma. Critical Reviews in Oncogenesis, 2015, 20, 217-225.	0.4	36

#	Article	IF	Citations
73	Changes in Retinoblastoma Cell Adhesion Associated with Optic Nerve Invasion. Molecular and Cellular Biology, 2009, 29, 6268-6282.	2.3	35
74	Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression. Oncotarget, 2014, 5, 9594-9608.	1.8	35
75	The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468.	12.8	35
76	Glutamate regulates retinal progenitors cells proliferation during development. European Journal of Neuroscience, 2006, 24, 969-980.	2.6	34
77	An E2F Binding-Deficient Rb1 Protein Partially Rescues Developmental Defects Associated with Rb1 Nullizygosity. Molecular and Cellular Biology, 2006, 26, 1527-1537.	2.3	34
78	Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine. Trends in Molecular Medicine, 2016, 22, 863-876.	6.7	34
79	Regenerative and restorative medicine for eye disease. Nature Medicine, 2022, 28, 1149-1156.	30.7	34
80	Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma. Clinical Cancer Research, 2019, 25, 7554-7564.	7.0	33
81	Developmental defects in Rb-deficient retinae. Vision Research, 2004, 44, 3323-3333.	1.4	31
82	Superselective Intraophthalmic Artery Chemotherapy. JAMA Ophthalmology, 2011, 129, 1490.	2.4	31
83	Brg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma. Development (Cambridge), 2015, 142, 4092-4106.	2.5	30
84	Development and characterization of a human orthotopic neuroblastoma xenograft. Developmental Biology, 2015, 407, 344-355.	2.0	30
85	Monitoring Ligand-Induced Protein Ordering in Drug Discovery. Journal of Molecular Biology, 2016, 428, 1290-1303.	4.2	29
86	AAV-mediated Local Delivery of Interferon-Î² for the Treatment of Retinoblastoma in Preclinical Models. NeuroMolecular Medicine, 2009, 11, 43-52.	3.4	28
87	Postâ€transcriptional gene expression control by <scp>NANOS</scp> is upâ€regulated and functionally important in <scp>pR</scp> bâ€deficient cells. EMBO Journal, 2014, 33, 2201-2215.	7.8	25
88	Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma. Pharmaceutical Research, 2014, 31, 3060-3072.	3.5	24
89	Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Reports, 2019, 28, 2331-2344.e8.	6.4	24
90	The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. Developmental Cell, 2022, 57, 1226-1240.e8.	7.0	24

#	Article	IF	Citations
91	Mosaic deletion ofRb arrests rod differentiation and stimulates ectopic synaptogenesis in the mouse retina. Journal of Comparative Neurology, 2006, 498, 112-128.	1.6	23
92	The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma. Cancer Immunology, Immunotherapy, 2018, 67, 615-626.	4.2	23
93	Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Letters, 2019, 442, 262-270.	7.2	23
94	Childhood Cancer and Developmental Biology. Current Topics in Developmental Biology, 2011, 94, 1-13.	2.2	20
95	Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma. Cancer Immunology, Immunotherapy, 2021, 70, 721-732.	4.2	17
96	Distinct Developmental Mechanisms Act Independently to Shape Biased Synaptic Divergence from an Inhibitory Neuron. Current Biology, 2020, 30, 1258-1268.e2.	3.9	15
97	A new model of tumor susceptibility following tumor suppressor gene inactivation. Cell Cycle, 2008, 7, 735-740.	2.6	14
98	Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. Cancer Research, 2015, 75, 5176-5186.	0.9	14
99	Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial. , 2020, 8, e000176.		14
100	Performance of a docking/molecular dynamics protocol for virtual screening of nutlin-class inhibitors of Mdmx. Journal of Molecular Graphics and Modelling, 2017, 74, 54-60.	2.4	12
101	Identification of a modular super-enhancer in murine retinal development. Nature Communications, 2022, 13, 253.	12.8	12
102	Stem Cells Expand Insights into Human Brain Evolution. Cell Stem Cell, 2016, 18, 425-426.	11.1	11
103	Reprogramming of mouse retinal neurons and standardized quantification of their differentiation in 3D retinal cultures. Nature Protocols, 2016, 11, 1955-1976.	12.0	11
104	Perspective: New genetic tools for studying retinal development and disease. Visual Neuroscience, 2005, 22, 553-560.	1.0	10
105	Statistical analysis of data from retroviral clonal experiments in the developing retina. Brain Research, 2008, 1192, 178-185.	2.2	8
106	Methylation profiling reveals novel molecular classes of rhabdomyosarcoma. Scientific Reports, 2021, 11, 22213.	3.3	8
107	Mutations and cancer: one or two historical perspectives?. Lancet Oncology, The, 2009, 10, 834.	10.7	7
108	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. JCO Precision Oncology, 2019, 3, 1-21.	3.0	6

#	Article	IF	Citations
109	An eye on retinal recovery. Nature, 2016, 540, 350-351.	27.8	5
110	Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.. Journal of Clinical Oncology, 2017, 35, 10542-10542.	1.6	5
111	Antigen cross-presentation in young tumor-bearing hosts promotes CD8 ⁺ T cell terminal differentiation. Science Immunology, 2022, 7, eabf6136.	11.9	5
112	Retinoblastoma (Rb) regulates laminar dendritic arbor reorganization in retinal horizontal neurons. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21111-21116.	7.1	4
113	The ATRX cDNA is prone to bacterial IS10 element insertions that alter its structure. SpringerPlus, 2014, 3, 222.	1.2	3
114	First pointwise encoding time reduction with radial acquisition (PETRA) implementation for catheter detection in interstitial high-dose-rate (HDR) brachytherapy. Brachytherapy, 2022, 21, 501-510.	0.5	3
115	Automated Tracing of Horizontal Neuron Processes During Retinal Development. Neurochemical Research, 2011, 36, 583-593.	3.3	2
116	Genetically Engineered Mouse and Orthotopic Human Tumor Xenograft Models of Retinoblastoma. Methods in Molecular Biology, 2015, 1267, 307-317.	0.9	2
117	Association of age at diagnosis and stage of disease with ATRX mutations in neuroblastoma.. Journal of Clinical Oncology, 2016, 34, 10525-10525.	1.6	2
118	Targeting retinoblastoma: therapeutic inhibition using catalytic antioxidant cerium oxide nanoparticles. FASEB Journal, 2013, 27, 1088.16.	0.5	2
119	Abstract 1543: Mining cancer-specific isoforms as CAR T-cell therapy targets for pediatric solid and brain tumors. , 2021, , .		1
120	Biology of Retinoblastoma. Pediatric Oncology, 2010, , 1-9.	0.5	1
121	Targeting the cell cycle for cancer therapy in rhabdomyosarcoma.. Journal of Clinical Oncology, 2017, 35, 10535-10535.	1.6	1
122	Comprehensive preclinical testing for neuroblastoma using orthotopic xenografts of a patient tumor.. Journal of Clinical Oncology, 2012, 30, e13584-e13584.	1.6	1
123	SYK expression in metastatic retinoblastoma.. Journal of Clinical Oncology, 2012, 30, e13544-e13544.	1.6	1
124	Special issue on retinal development. Brain Research, 2008, 1192, 1-2.	2.2	0
125	Current and emerging therapy for improving outcomes in patients with intraocular retinoblastoma. Expert Opinion on Orphan Drugs, 2015, 3, 1155-1166.	0.8	0
126	Retinoblastoma Tumorigenesis. , 2019, , 67-77.		0

#	Article	IF	Citations
127	Abstract 2289: Empowering point-and-click genomic analysis with large pediatric genomic reference data on St. Jude Cloud. , 2021, , .		0
128	Cellular and genetic events in retinoblastoma tumorigenesis. , 2007, , 405-409.		0
129	Incorporating PARP inhibitors in translational studies for Ewingâ€™s sarcoma.. Journal of Clinical Oncology, 2014, 32, e21025-e21025.	1.6	0
130	Preclinical evaluation of PARP inhibitors in combination with DNA-damaging agents in a Ewing sarcoma orthotopic xenograft model.. Journal of Clinical Oncology, 2014, 32, 10073-10073.	1.6	0
131	Molecular analysis of solid tumors (MAST): A protocol for comprehensive preclinical evaluation of pediatric solid tumors.. Journal of Clinical Oncology, 2014, 32, 10036-10036.	1.6	0
132	Retinoblastoma Tumorigenesis. , 2015, , 61-68.		0
133	The Childhood Solid Tumor Network: A St. Jude Initiative.. Journal of Clinical Oncology, 2015, 33, e21022-e21022.	1.6	0
134	Loss of STAG2 expression and prognosis in Ewing sarcoma family of tumors.. Journal of Clinical Oncology, 2015, 33, 10024-10024.	1.6	0
135	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. Journal of the Endocrine Society, 2019, 3, .	0.2	0